Skip to main content
S 3390 117th Congress Senate Health Cardiovascular and respiratory health Drug safety, medical device, and laboratory regulation Drug therapy Health care quality Health facilities and institutions Health information and medical records Health promotion and preventive care Medical research Neurological disorders Research administration and funding

CCM–CARE Act of 2021

Introduced: December 14, 2021 Introduced by: Luján, Ben Ray Democratic · New Mexico See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 14, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Dec 14, 2021
Introduced in Senate
 Plain-English summary Congressional Research Service

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2021 or the CCM-CARE Act of 2021

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

What's happening now December 14, 2021

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1